These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 14529382

  • 1. Overview: translating Hsp90 biology into Hsp90 drugs.
    Workman P.
    Curr Cancer Drug Targets; 2003 Oct; 3(5):297-300. PubMed ID: 14529382
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Heat shock protein 90: novel target for cancer therapy].
    Chen Y, Ding J.
    Ai Zheng; 2004 Aug; 23(8):968-74. PubMed ID: 15301726
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Development of small molecule Hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification.
    Neckers L.
    Curr Med Chem; 2003 May; 10(9):733-9. PubMed ID: 12678776
    [Abstract] [Full Text] [Related]

  • 6. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.
    Smith V, Sausville EA, Camalier RF, Fiebig HH, Burger AM.
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):126-37. PubMed ID: 15841378
    [Abstract] [Full Text] [Related]

  • 7. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
    Powers MV, Workman P.
    Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S125-35. PubMed ID: 17259553
    [Abstract] [Full Text] [Related]

  • 8. Altered states: selectively drugging the Hsp90 cancer chaperone.
    Workman P.
    Trends Mol Med; 2004 Feb; 10(2):47-51. PubMed ID: 15106614
    [Abstract] [Full Text] [Related]

  • 9. [Molecular chaperone HSP90 as a novel target for cancer chemotherapy].
    Miyata Y.
    Nihon Yakurigaku Zasshi; 2003 Jan; 121(1):33-42. PubMed ID: 12617036
    [Abstract] [Full Text] [Related]

  • 10. Inhibitors of the HSP90 molecular chaperone: current status.
    Sharp S, Workman P.
    Adv Cancer Res; 2006 Jan; 95():323-48. PubMed ID: 16860662
    [Abstract] [Full Text] [Related]

  • 11. Hsp90: an emerging target for breast cancer therapy.
    Beliakoff J, Whitesell L.
    Anticancer Drugs; 2004 Aug; 15(7):651-62. PubMed ID: 15269596
    [Abstract] [Full Text] [Related]

  • 12. Altered Hsp90 function in cancer: a unique therapeutic opportunity.
    Bagatell R, Whitesell L.
    Mol Cancer Ther; 2004 Aug; 3(8):1021-30. PubMed ID: 15299085
    [Abstract] [Full Text] [Related]

  • 13. Hsp90 as a therapeutic target in prostate cancer.
    Solit DB, Scher HI, Rosen N.
    Semin Oncol; 2003 Oct; 30(5):709-16. PubMed ID: 14571418
    [Abstract] [Full Text] [Related]

  • 14. Mechanistic studies on Hsp90 inhibition by ansamycin derivatives.
    Onuoha SC, Mukund SR, Coulstock ET, Sengerovà B, Shaw J, McLaughlin SH, Jackson SE.
    J Mol Biol; 2007 Sep 14; 372(2):287-97. PubMed ID: 17662999
    [Abstract] [Full Text] [Related]

  • 15. The Hsp90 chaperone complex as a novel target for cancer therapy.
    Goetz MP, Toft DO, Ames MM, Erlichman C.
    Ann Oncol; 2003 Aug 14; 14(8):1169-76. PubMed ID: 12881371
    [Abstract] [Full Text] [Related]

  • 16. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress.
    Workman P, Burrows F, Neckers L, Rosen N.
    Ann N Y Acad Sci; 2007 Oct 14; 1113():202-16. PubMed ID: 17513464
    [Abstract] [Full Text] [Related]

  • 17. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
    Stravopodis DJ, Margaritis LH, Voutsinas GE.
    Curr Med Chem; 2007 Oct 14; 14(29):3122-38. PubMed ID: 18220746
    [Abstract] [Full Text] [Related]

  • 18. Antimyeloma activity of heat shock protein-90 inhibition.
    Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Kung AL, Davies FE, Morgan G, Akiyama M, Shringarpure R, Munshi NC, Richardson PG, Hideshima T, Chauhan D, Gu X, Bailey C, Joseph M, Libermann TA, Rosen NS, Anderson KC.
    Blood; 2006 Feb 01; 107(3):1092-100. PubMed ID: 16234364
    [Abstract] [Full Text] [Related]

  • 19. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.
    Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, Burrows FJ.
    Nature; 2003 Sep 25; 425(6956):407-10. PubMed ID: 14508491
    [Abstract] [Full Text] [Related]

  • 20. 17-Allyamino-17-demethoxygeldanamycin and 17-NN-dimethyl ethylene diamine-geldanamycin have cytotoxic activity against multiple gynecologic cancer cell types.
    Gossett DR, Bradley MS, Jin X, Lin J.
    Gynecol Oncol; 2005 Feb 25; 96(2):381-8. PubMed ID: 15661225
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.